The development and widespread use of HAART has resulted in dramatic decreases in AIDS-related mortality and morbidity; however, issues with HAART - including potency, dosing frequency, tolerability, toxicity and exacerbation of co-morbidities - have prevented some patient's from being successfully treated. Fortunately, since HAART's introduction in 1996, there have been numerous ARVs developed and approved that have significantly improved on many of the problematic characteristics of HAART. With the arrival of each new ARV, clinicians have had to weigh the potential benefits and risks of changing a patient's current HAART regimen while being mindful that while many studies have demonstrated that some patients benefit from switching one or more of the ARVs in their HAART regimen, other studies have shown that these switches are not always advantageous.
This debate-style dinner program series will feature two nationally known HIV thought leaders and a local moderator and will use a case-based format to review and discuss relevant clinical research regarding which factors should play a role in ARV switching, including patient and ARV selection, and how to achieve the benefits of ARV switching with minimal risk. Because the focus of the programs will be on case studies, participants will need to be familiar with the breadth of current data that may be applied and discussed. Therefore, prior to attending a dinner program, participants will view an Internet presentation that summarizes and discusses the key data that will be used during each case argument. CLICK HERE to view the on-demand internet symposium.
This program has been designed to help clinicians learn more about the advantages and disadvantages of various switching strategies which will improve their professional skills and enhance their ability to provide optimal patient care, which is expected to result in improved patient outcomes.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
| Tuesday, June 9, 2015 New York, NY |
Thursday, June 25, 2015 Los Angeles, CA |
| Wednesday, June 10, 2015 Miami, FL |
Tuesday, June 30, 2015 Detroit, MI |
| Thursday, June 11, 2015 San Diego, CA |
Wednesday, July 1, 2015 Chicago, IL |
| Thursday, June 18, 2015 San Francisco, CA |
Tuesday, July 7, 2015 Kansas City, MO |
| Thursday, June 18, 2015 Durham, NC |
Tuesday, July 14, 2015 Houston, TX |
|
Wednesday, June 24, 2015
Phoenix, AZ |
Wednesday, July 15, 2015 Pasadena, CA |
| Roberto C. Arduino, MD Professor of Medicine, UT Director of Research Thomas Street Clinic The University of Texas-Houston Houston, Texas |
Eric S. Daar, MD |
|
Joseph Eron, MD Professor University of North Carolina School of Medicine Chapel Hill, North Carolina |
Ian Frank, MD Professor of Medicine Director, Clinical Therapeutics Program Penn Center for AIDS Research Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania |
|
W. David Hardy, MD Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California |
Trevor Hawkins, MD |
|
Charles B. Hicks, MD Professor of Clinical Medicine Director, Owen Clinic University of California, San Diego San Diego, California |
Dushyantha T. Jayaweera, MD |
|
Michael Sension, MD Medical Director, HIV Clinical Research Broward Health Fort Lauderdale, Florida |
Renslow Sherer, MD |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
